Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases
Background. In Mexico, asthma is one of the top twenty causes of disease with 254,713 new cases reported in 2019. According to Phase 3 of the International Study of Asthma and Allergies in Childhood, the prevalence of asthma ranged from 5 to 14% in 6 Mexican cities with varied geographic conditions...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Colegio Mexicano de Inmunología Clínica y Alergia, A.C.
2024-04-01
|
| Series: | Revista Alergia México |
| Subjects: | |
| Online Access: | https://revistaalergia.mx/ojs/index.php/ram/article/view/1279 |
| _version_ | 1797193778571771904 |
|---|---|
| author | Maria del Carmen Cano Salas José Luis Miguel Reyes Karen Sánchez Trejo Erika del Carmen López Estrada Jorge Salas Hernández Monserrat Evelia Arroyo Rojas Mauricio Castañeda Valdivia Monserrat Escobar Preciado Silvia Guzmán Vázquez Sergio Ricardo García-García Herman Soto Molina |
| author_facet | Maria del Carmen Cano Salas José Luis Miguel Reyes Karen Sánchez Trejo Erika del Carmen López Estrada Jorge Salas Hernández Monserrat Evelia Arroyo Rojas Mauricio Castañeda Valdivia Monserrat Escobar Preciado Silvia Guzmán Vázquez Sergio Ricardo García-García Herman Soto Molina |
| author_sort | Maria del Carmen Cano Salas |
| collection | DOAJ |
| description |
Background. In Mexico, asthma is one of the top twenty causes of disease with 254,713 new cases reported in 2019. According to Phase 3 of the International Study of Asthma and Allergies in Childhood, the prevalence of asthma ranged from 5 to 14% in 6 Mexican cities with varied geographic conditions. The burden of this disease impacts the health system in terms of direct costs through increased hospitalization and treatment costs; and indirect costs such as school and work absenteeism. Methods. A retrospective, longitudinal observational study comprised by data from 247 female asthma patients, annual direct costs were estimated including: visits, laboratory tests, pharmacological treatment and management of crisis or exacerbations, to determine the annal burden of the disease from an institutional perspective and according to Global Initiative for Asthma classification. Results. The average annual cost was $43,813.92, which increased in relation to the need of inhaled corticosteroids and long-acting beta agonists dosage increase. The average doctor’s appointment cost was $2,004.57, $982.82 for crisis management and $2,645.95 for laboratory testing. Pharmacological treatment represented the main economic burden with an annual average cost of $38,180.58. Conclusions. The present analysis shows the severity of asthma and auxiliary treatments like biologics were the main factors that increased direct attention costs. The results highlight a high economic burden for asthma within the context of the third level of care in Mexico’s public health system.
|
| first_indexed | 2024-04-24T05:45:48Z |
| format | Article |
| id | doaj.art-5dc897bbd1c84ed7b68c88b51e5a3cb7 |
| institution | Directory Open Access Journal |
| issn | 0002-5151 2448-9190 |
| language | English |
| last_indexed | 2024-04-24T05:45:48Z |
| publishDate | 2024-04-01 |
| publisher | Colegio Mexicano de Inmunología Clínica y Alergia, A.C. |
| record_format | Article |
| series | Revista Alergia México |
| spelling | doaj.art-5dc897bbd1c84ed7b68c88b51e5a3cb72024-04-23T14:21:05ZengColegio Mexicano de Inmunología Clínica y Alergia, A.C.Revista Alergia México0002-51512448-91902024-04-0171110.29262/ram.v71i1.1279Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory DiseasesMaria del Carmen Cano Salas0José Luis Miguel Reyes1Karen Sánchez Trejo2Erika del Carmen López Estrada3Jorge Salas Hernández4Monserrat Evelia Arroyo Rojas5Mauricio Castañeda Valdivia6Monserrat Escobar Preciado7Silvia Guzmán Vázquez8Sergio Ricardo García-García9Herman Soto Molina10Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, MéxicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, MéxicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, MéxicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, MéxicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, MéxicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, MéxicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, MéxicoInstituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de México, MéxicoHS Estudios FarmacoeconómicosHS Estudios FarmacoeconómicosHS Estudios Farmacoeconómicos Background. In Mexico, asthma is one of the top twenty causes of disease with 254,713 new cases reported in 2019. According to Phase 3 of the International Study of Asthma and Allergies in Childhood, the prevalence of asthma ranged from 5 to 14% in 6 Mexican cities with varied geographic conditions. The burden of this disease impacts the health system in terms of direct costs through increased hospitalization and treatment costs; and indirect costs such as school and work absenteeism. Methods. A retrospective, longitudinal observational study comprised by data from 247 female asthma patients, annual direct costs were estimated including: visits, laboratory tests, pharmacological treatment and management of crisis or exacerbations, to determine the annal burden of the disease from an institutional perspective and according to Global Initiative for Asthma classification. Results. The average annual cost was $43,813.92, which increased in relation to the need of inhaled corticosteroids and long-acting beta agonists dosage increase. The average doctor’s appointment cost was $2,004.57, $982.82 for crisis management and $2,645.95 for laboratory testing. Pharmacological treatment represented the main economic burden with an annual average cost of $38,180.58. Conclusions. The present analysis shows the severity of asthma and auxiliary treatments like biologics were the main factors that increased direct attention costs. The results highlight a high economic burden for asthma within the context of the third level of care in Mexico’s public health system. https://revistaalergia.mx/ojs/index.php/ram/article/view/1279Adverse reaction to the drug |
| spellingShingle | Maria del Carmen Cano Salas José Luis Miguel Reyes Karen Sánchez Trejo Erika del Carmen López Estrada Jorge Salas Hernández Monserrat Evelia Arroyo Rojas Mauricio Castañeda Valdivia Monserrat Escobar Preciado Silvia Guzmán Vázquez Sergio Ricardo García-García Herman Soto Molina Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases Revista Alergia México Adverse reaction to the drug |
| title | Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases |
| title_full | Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases |
| title_fullStr | Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases |
| title_full_unstemmed | Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases |
| title_short | Economic burden assessment for the management of asthma patients at Mexico’s National Institute for Respiratory Diseases |
| title_sort | economic burden assessment for the management of asthma patients at mexico s national institute for respiratory diseases |
| topic | Adverse reaction to the drug |
| url | https://revistaalergia.mx/ojs/index.php/ram/article/view/1279 |
| work_keys_str_mv | AT mariadelcarmencanosalas economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT joseluismiguelreyes economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT karensancheztrejo economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT erikadelcarmenlopezestrada economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT jorgesalashernandez economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT monserrateveliaarroyorojas economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT mauriciocastanedavaldivia economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT monserratescobarpreciado economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT silviaguzmanvazquez economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT sergioricardogarciagarcia economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases AT hermansotomolina economicburdenassessmentforthemanagementofasthmapatientsatmexicosnationalinstituteforrespiratorydiseases |